Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to $45.3 million.

  • Iovance Biotherapeutics' Accumulated Depreciation & Amortization changed N/A to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year change of. This contributed to the annual value of $36.0 million for FY2024, which is 2904.38% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $45.3 million for Q3 2025.
  • In the past 5 years, Iovance Biotherapeutics' Accumulated Depreciation & Amortization registered a high of $45.3 million during Q3 2025, and its lowest value of $19.4 million during Q1 2023.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $30.9 million (2024), whereas its average is $32.0 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 5944.56% in 2024, then skyrocketed by 2548.32% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Accumulated Depreciation & Amortization stood at $27.9 million in 2023, then rose by 29.04% to $36.0 million in 2024, then grew by 25.83% to $45.3 million in 2025.
  • Its last three reported values are $45.3 million in Q3 2025, $42.1 million for Q2 2025, and $38.8 million during Q1 2025.